BIOVIE INC (BIVI)

US09074F2074 - Common Stock

3.41  +0.22 (+6.9%)

After market: 3.29 -0.12 (-3.52%)

Fundamental Rating

2

Overall BIVI gets a fundamental rating of 2 out of 10. We evaluated BIVI against 565 industry peers in the Biotechnology industry. The financial health of BIVI is average, but there are quite some concerns on its profitability. BIVI does not seem to be growing, but still is valued expensively.



0

1. Profitability

1.1 Basic Checks

BIVI had negative earnings in the past year.
In the past year BIVI has reported a negative cash flow from operations.
BIVI had negative earnings in each of the past 5 years.
BIVI had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

BIVI has a worse Return On Assets (-130.93%) than 82.53% of its industry peers.
Looking at the Return On Equity, with a value of -212.86%, BIVI is doing worse than 70.05% of the companies in the same industry.
Industry RankSector Rank
ROA -130.93%
ROE -212.86%
ROIC N/A
ROA(3y)-1103.91%
ROA(5y)-1006.53%
ROE(3y)-1559.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

BIVI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, BIVI has less shares outstanding
BIVI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for BIVI has been reduced compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -18.57, we must say that BIVI is in the distress zone and has some risk of bankruptcy.
BIVI has a Altman-Z score of -18.57. This is amonst the worse of the industry: BIVI underperforms 85.38% of its industry peers.
BIVI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.57
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

BIVI has a Current Ratio of 2.57. This indicates that BIVI is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.57, BIVI is not doing good in the industry: 70.41% of the companies in the same industry are doing better.
A Quick Ratio of 2.57 indicates that BIVI has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.57, BIVI is doing worse than 69.70% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.57
Quick Ratio 2.57

1

3. Growth

3.1 Past

The earnings per share for BIVI have decreased strongly by -239.61% in the last year.
EPS 1Y (TTM)-239.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-223.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BIVI will show a very strong growth in Earnings Per Share. The EPS will grow by 23.11% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22.85%
EPS Next 2Y30.83%
EPS Next 3Y25.16%
EPS Next 5Y23.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BIVI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIVI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

BIVI's earnings are expected to grow with 25.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.83%
EPS Next 3Y25.16%

0

5. Dividend

5.1 Amount

No dividends for BIVI!.
Industry RankSector Rank
Dividend Yield N/A

BIOVIE INC

NASDAQ:BIVI (11/18/2024, 8:11:37 PM)

After market: 3.29 -0.12 (-3.52%)

3.41

+0.22 (+6.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap60.56M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -130.93%
ROE -212.86%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.57
Quick Ratio 2.57
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-239.61%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y22.85%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y